Search
-
GRK2‐ Targeted Knockdown as Therapy for Multiple System Atrophy
(Movement Disorders. vol. 38, n° 7, pp. 1336-1340, 2023-07)Article de revueOpen access -
Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder
(Neurology. vol. 101, n° 4, pp. E438-E450, 2023-07-25)Article de revue -
Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials
(Nature Medicine. vol. 29, n° 6, pp. 1487-1499, 2023-06-01)Article de revueOpen access -
Striatopallidal cannabinoid type-1 receptors mediate amphetamine-induced sensitization
(2023-10)Document de travail - Pré-publicationOpen access -
Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome
(Cells. vol. 12, n° 15, pp. 1927, 2023-07-25)Article de revueOpen access -
Does food use disorder exist? Item response theory analyses of a food use disorder adapted from the DSM-5 substance use disorder criteria in a treatment seeking clinical sample
(Drug and Alcohol Dependence. vol. 251, 2023-10-01)Article de revue -
Camkiiβ in neuronal development and plasticity: An emerging candidate in brain diseases
(International Journal of Molecular Sciences. vol. 21, n° 19, pp. 1-15, 2020-10-01)Article de revueOpen access -
Effect of cognitive rehabilitation on neuropsychological and semiecological testing and on daily cognitive functioning in multiple sclerosis: The REACTIV randomized controlled study
(2020-08-15)Document de travail - Pré-publicationOpen access -
Structural progression of Alzheimer's disease over decades: The MRI staging scheme
(Brain Communications. vol. 4, n° 3, 2022-04-28)Article de revueOpen access -
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment
(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 6, 2023-09-22)Article de revueOpen access